(-0.07%) 5 465.31 points
(0.08%) 39 143 points
(0.16%) 17 746 points
(0.06%) $80.88
(-5.04%) $2.62
(-0.80%) $2 312.20
(-0.06%) $28.85
(3.28%) $1 018.80
(0.33%) $0.936
(0.75%) $10.68
(0.50%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A...
Stats | |
---|---|
Dagens volum | 81 878 |
Gjennomsnittsvolum | 120 683 |
Markedsverdi | 56.22M |
EPS | $-3.00 ( Q2 | 2023-08-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.515 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.161 (5.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-11 | Flagship Ventures Fund V General Partner Llc | Sell | 113 960 | Common Stock |
2023-08-11 | Eli Lilly & Co | Buy | 1 718 493 | Common Stock |
2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
2023-08-11 | Cole Douglas G. | Sell | 683 | Stock Option (Right to Buy) |
2023-08-11 | Oesterle Stephen N. | Sell | 683 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
69.03 |
Last 96 transactions |
Buy: 15 034 169 | Sell: 5 311 777 |
Volum Korrelasjon
Sigilon Therapeutics, Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
DICE | 0.802 |
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Sigilon Therapeutics, Korrelasjon - Valuta/Råvare
Sigilon Therapeutics, Økonomi
Annual | 2022 |
Omsetning: | $12.94M |
Bruttogevinst: | $12.94M (100.00 %) |
EPS: | $-1.340 |
FY | 2022 |
Omsetning: | $12.94M |
Bruttogevinst: | $12.94M (100.00 %) |
EPS: | $-1.340 |
FY | 2021 |
Omsetning: | $9.60M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.43 |
FY | 2020 |
Omsetning: | $13.37M |
Bruttogevinst: | $13 374.00 (0.10 %) |
EPS: | $-7.55 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Sigilon Therapeutics,
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.